VolitionRx’s (VNRX) Buy Rating Reiterated at D. Boral Capital

D. Boral Capital reaffirmed their buy rating on shares of VolitionRx (NYSE:VNRX) in a report published on Thursday,Benzinga reports. D. Boral Capital currently has a $5.00 price target on the stock.

A number of other research firms have also weighed in on VNRX. StockNews.com initiated coverage on shares of VolitionRx in a research report on Friday, January 31st. They issued a “sell” rating on the stock. Benchmark reiterated a “hold” rating on shares of VolitionRx in a report on Friday, November 22nd.

VolitionRx Trading Up 6.1 %

VNRX stock opened at $0.62 on Thursday. The firm’s fifty day simple moving average is $0.62 and its two-hundred day simple moving average is $0.65. VolitionRx has a twelve month low of $0.43 and a twelve month high of $1.22.

Insider Buying and Selling

In other news, CEO Cameron John Reynolds bought 139,811 shares of the firm’s stock in a transaction on Monday, December 9th. The stock was acquired at an average cost of $0.57 per share, with a total value of $79,692.27. Following the transaction, the chief executive officer now directly owns 2,117,404 shares in the company, valued at approximately $1,206,920.28. This trade represents a 7.07 % increase in their position. The acquisition was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, Director Guy Archibald Innes purchased 174,764 shares of the company’s stock in a transaction dated Monday, December 9th. The shares were purchased at an average cost of $0.57 per share, for a total transaction of $99,615.48. Following the transaction, the director now directly owns 617,085 shares in the company, valued at approximately $351,738.45. This represents a 39.51 % increase in their position. The disclosure for this purchase can be found here. Insiders have purchased 358,266 shares of company stock valued at $204,212 in the last 90 days. Company insiders own 12.80% of the company’s stock.

Institutional Investors Weigh In On VolitionRx

A hedge fund recently raised its stake in VolitionRx stock. Geode Capital Management LLC boosted its holdings in shares of VolitionRx Limited (NYSE:VNRX) by 15.1% during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 730,448 shares of the company’s stock after buying an additional 95,900 shares during the quarter. Geode Capital Management LLC owned approximately 0.79% of VolitionRx worth $439,000 as of its most recent SEC filing. Institutional investors and hedge funds own 8.09% of the company’s stock.

VolitionRx Company Profile

VolitionRx Limited, a multi-national epigenetics company, engages in the development of blood tests to help diagnose and monitor a range of cancers, and sepsis and COVID-19 in the United States and internationally. The company offers Nu.Q Vet, a cancer screening test for dogs and other animals; Nu.Q Nets for monitoring the immune system; Nu.Q Cancer for monitoring disease progression, response to treatment and minimal residual disease; Capture-PCR, an isolating and capturing circulating tumor derived DNA from plasma samples for early cancer detection; and Nu.Q Discover, a solution to profiling nucleosomes.